🔗 Share this article Individuals Stopping Slimming Medications Put On Pounds at a Quadrupled Rate Compared to Dieters Obesity treatment involves ongoing approaches. Fresh analysis suggests that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle programs. Research printed in a leading health publication shows that while overweight individuals often shed a large proportion of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month upon discontinuation. "Individuals purchasing such drugs must be informed of the potential of rapid rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb. Such speed of regain suggests a return to starting mass within about a year and a half. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, contrasted the effects of these new drugs with conventional dieting. The team note that people who shed pounds through lifestyle changes alone usually have a less rapid creep back—around 100 grams monthly—once they finish. Explaining the Fast Regain Nutrition scientists believe the mode of action of the injections explains the heightened regain. GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness. "Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher. "Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely." A Lifelong Condition? Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals contend that, due to the high risk of relapse, the therapy should be considered ongoing. This opinion is echoed by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," similar to managing diseases like hypertension. User Experiences People who have come off the jabs report a sudden resurgence of appetite. "It felt as if a trigger flipping and I was suddenly ravenous," said one woman. This challenge is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy. Widespread Use Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among females compared to men. The middle-aged demographic shows the highest level of interest. A large proportion obtain the medications through private healthcare rather than public health services. Ultimately, experts caution that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success relies on combined behavioural support.
Obesity treatment involves ongoing approaches. Fresh analysis suggests that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle programs. Research printed in a leading health publication shows that while overweight individuals often shed a large proportion of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month upon discontinuation. "Individuals purchasing such drugs must be informed of the potential of rapid rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb. Such speed of regain suggests a return to starting mass within about a year and a half. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, contrasted the effects of these new drugs with conventional dieting. The team note that people who shed pounds through lifestyle changes alone usually have a less rapid creep back—around 100 grams monthly—once they finish. Explaining the Fast Regain Nutrition scientists believe the mode of action of the injections explains the heightened regain. GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness. "Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher. "Stopping of this medication leads to appetite is unsuppressed, making excessive eating far more likely." A Lifelong Condition? Health authorities recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals contend that, due to the high risk of relapse, the therapy should be considered ongoing. This opinion is echoed by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," similar to managing diseases like hypertension. User Experiences People who have come off the jabs report a sudden resurgence of appetite. "It felt as if a trigger flipping and I was suddenly ravenous," said one woman. This challenge is compounded if users have not adopted sustainable dietary or behavioural modifications during therapy. Widespread Use Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among females compared to men. The middle-aged demographic shows the highest level of interest. A large proportion obtain the medications through private healthcare rather than public health services. Ultimately, experts caution that while the jabs are effective tools for weight loss, they are not a standalone fix and long-term success relies on combined behavioural support.